Sex differences in long-term mortality among acute myocardial infarction patients: Results from the ISAR-RISK and ART studies

Romy Ubrich¹, Petra Barthel¹, Bernhard Haller², Katerina Hnatkova³, Katharina Maria Huster¹, Alexander Steger¹, Alexander Müller¹, Marek Malik³‡, Georg Schmidt¹,‡*, Katharina Maria Huster¹

¹ Innere Medizin I, Klinikum rechts der Isar, Technische Universität München, Munich, Germany, ² Institut für Medizinische Statistik und Epidemiologie, Technische Universität München, Munich, Germany, ³ National Heart and Lung Institute, Imperial College, London, England, 4 DZHK (German Centre for Cardiovascular Research), Partner site Munich Heart Alliance, Munich, Germany

These authors contributed equally to this work.
‡ These authors are senior authors on this work.
* gschmidt@tum.de

Abstract

Background
Mortality rates in females who survived acute myocardial infarction (AMI) exceed those in males. Differences between sexes in age, cardiovascular risk factors and revascularization therapy have been proposed as possible reasons.

Objective
To select sets of female and male patients comparable in respect of relevant risk factors in order to compare the sex-specific risk in a systematic manner.

Methods
Data of the ISAR-RISK and ART studies were investigated. Patients were enrolled between 1996 and 2005 and suffered from AMI within 4 weeks prior to enrolment. Patients of each sex were selected with 1:1 equivalent age, previous AMI history, sinus-rhythm presence, hypertension, diabetes mellitus, smoking status, left ventricular ejection fraction (LVEF), and revascularization therapy. Survival times were compared between sex groups in the whole study cohort and in the matched cohort.

Results
Of 3840 consecutive AMI survivors, 994 (25.9%) were females and 2846 (74.1%) were males. Females were older and suffered more frequently from hypertension and diabetes mellitus. In the whole cohort, females showed an increased mortality with a hazard ratio (HR) of 1.54 compared to males (p<0.0001). The matched cohort comprised 802 patients of each sex and revealed a trend towards poorer survival in females (HR for female sex 1.14; p = 0.359). However, significant mortality differences with a higher risk in matched females...
was observed during the first year after AMI (HR = 1.61; p = 0.045) but not during the subsequent years.

**Conclusion**

Matched sub-groups of post-AMI patients showed a comparable long-term mortality. However, a female excess mortality remained during first year after AMI and cannot be explained by differences in age, cardiovascular risk factors, and modes of acute treatment. Other causal factors, including clinical as well as psychological and social aspects, need to be considered. Female post-AMI patients should be followed more actively particularly during the first year after AMI.

**Introduction**

Survivors of acute myocardial infarction (AMI) are at increased risk of subsequent death due to, among others, re-infarction, arrhythmic events, or heart failure. In practically all existing reports [1–3], significantly higher crude follow-up mortality was observed in females compared to males. This has been attributed to the differences in age [4–7], comorbidities [4–6,8], symptom presentation [9–11] and pathophysiology of the underlying coronary artery disease [12–16]. Nevertheless, no solid data exist on the impact of these common sex differences on the post-AMI survival. In particular, data on the importance of the common sex differences are missing in patients treated according to contemporary standards including acute coronary interventions and guideline-based acute pharmacologic treatment.

Whilst the differences between females and males in the survival and severity of AMI have been the topic of a large number of investigations, direct comparisons between large groups of patients of both sexes carefully matched for a number of clinical characteristics are lacking. Such comparisons of case-by-case matched sex groups appear to be the most transparent method for confirming or eliminating the roles that different clinical and pathophysiological factors may play in the sex differences of post-AMI survival and prognosis. Having this in mind, we selected large sex-specific sub-groups of post-AMI patients case-by-case matched for potential confounders that included a majority of the factors that have previously been proposed as the sources of post-AMI sex differences [4–16]. This allowed us to investigate whether these confounders explain the known sex differences in post-AMI survival.

**Methods**

Patients of two previously reported prospective cohort studies, namely the ISAR-RISK [17] and ART [18] studies, were investigated. ISAR-RISK was a prospective cohort study aiming to prospectively validate heart rate turbulence in patients who had survived the first 30 days after initial hospitalization for an acute myocardial infarction [19]. ART was a prospective cohort study in the same kind of patients aiming to develop noninvasive risk predictors on the basis of 30-minute high resolution recordings of ECG, blood pressure and respiration [20–24].

ISAR-RISK patients were recruited between January 1996 and April 2000, ART patients between May 2000 and March 2005 at Klinikum rechts der Isar and Deutsches Herzzentrum München, both in Munich (Germany). The last follow-up for both studies was in May 2010. Study patients suffered from AMI within 4 weeks prior to enrolment. AMI was diagnosed if 2 of the following criteria were present: 1) chest pain lasting ≥20 minutes prior to admission, 2)
creatine kinase-MB levels above double upper normal limit of our laboratory, 3) ST-Segment elevation of $\geq 0.1$ mV in two or more limb leads and/or $\geq 0.2$ mV in two or more contiguous precordial leads.

Revascularization was performed using percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) or thrombolysis. Conservative revascularization therapy was performed in case of severe underlying diseases such as malignancies, diffuse obstructive coronary artery disease (CAD) and refusal of coronary angiography by the patient.

Both source studies were approved by the local ethics committee of Technische Universität München (Munich, Germany). All patients provided oral (ISAR-RISK) or written (ART) informed consent.

Clinical variables

On hospital admission, heart rate, blood pressure, serum creatinine and cardiac enzymes were measured and a standard 12-lead ECG recorded in all patients. Left ventricular ejection fraction (LVEF) was quantified by either echocardiography or angiography. Atrial fibrillation was diagnosed if present in the resting ECG at admission. Patients were considered to suffer from diabetes if they were already diagnosed and were receiving treatment or if their fasting blood glucose concentration repeatedly exceeded 11 mmol/L during the hospitalization for the index AMI. Patients were considered to suffer from hypertension if they were already diagnosed and were receiving treatment or if their arterial pressure repeatedly exceeded 140/90 mmHg during the hospitalization. Patients were considered to be smokers if they reported smoking at hospital admission.

Follow-up and endpoints

Patients were followed-up every six months by clinical appointments. In case of non-attendance, patients were contacted personally or their status was assessed through their general practitioner. If the contact was lost, the local population registry provided a new address or confirmed the death of the patient. The primary endpoint was 5-year all-cause mortality.

Composition of study cohort

A total of 4141 patients of the ISAR-RISK and the ART study were admitted to the hospital with AMI. Of these, 3854 patients survived the first 30 days after hospital admission. We further excluded 14 patients due to incomplete clinical baseline data. In the remaining cohort of 3840 patients, 994 (25.9%) were female and 2846 (74.1%) were male, respectively. In total, 29 (0.8%) patients were lost to follow-up (<1 year) and were censored at their last attended clinical appointment.

Statistics

Cohorts of 1:1 matched female and male patients were selected among all patients of the dataset to account for differences in known possible confounders of follow-up mortality allowing a comparison of survival times for females and males who are similar in relevant patient characteristics. For each female patient, a corresponding male patient was selected with corresponding age, LVEF, hypertension, diabetes mellitus, smoking status, non-sinus rhythm, previous AMI, and the category of revascularization therapy (i.e. PCI, CABG, thrombolysis, or “no intervention” which included patients without obstructive CAD and those treated conservatively in the presence of severe underlying disease, diffuse obstructive coronary artery disease, or coronary angiography refusal).
Only patients within the convex hull of the variables for females and males were considered to ensure similarity between matched female and male patients [25]. Within these patients, an exact match of the categorical variables (hypertension, diabetes mellitus, smoking status, non-sinus rhythm, previous AMI, and revascularization therapy) was performed. For quantitative measures, i.e. age and LVEF, a nearest-neighbor matching based on the propensity score [26] was used to find the best control match. Matching was performed using the R package “MatchIt” [27].

Continuous variables are presented as mean ± standard deviation (SD). Categorical data are presented as absolute frequencies and percentages. Group means were compared by two-tailed t-tests using Welch’s adaption for different group variances. Frequencies were compared by Chi-Square tests of Fisher exact tests. Survival curves were estimated by the Kaplan–Meier method and compared using the log-rank test. Confidence bands of the Kaplan–Meier curves were calculated using the bootstrap technique with 10,000 repetitions. Cox regression models were fit to the data to estimate hazard ratios with corresponding 95% confidence intervals (CI). Survival times were compared between females and males in the whole study cohort and in a cohort matched with regard to relevant confounders.

Additional survival analyses were performed to compare mortality risks for different time intervals. Specifically, separate analyses considered the sex survival differences during the first year after the index AMI, and the sex survival differences among patients who survived for at least one year after the index AMI.

A p-value of <0.05 was considered as statistically significant. IBM SPSS Statistics 22.0 (IBM SPSS, Inc.) and R 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria) were used for the statistical analyses.

Results

Complete cohort

Table 1 shows the clinical characteristics of the complete cohort at baseline hospitalization. Females were older and suffered more frequently from hypertension and diabetes mellitus. They were less often active smokers. A previous AMI in the past medical history was more often among males. Fewer females than males were in sinus rhythm. Males showed a significantly worse renal function than females. CK-levels at admission were significantly higher in males than in females. There were no significant LVEF differences between sexes.

Coronary angiography was performed in 99.2% and 99.6% of female and male patients, respectively. A non-obstructive CAD was significantly more often noted in females than in males. Accordingly, females were more frequently treated conservatively regarding PCI revascularization. Males showed a significantly higher rate of three-vessel CAD. Thrombolysis and CABG were infrequent in both groups without significant differences.

Drug therapy after AMI with acetylsalicylic acid (ASS), betablockers, angiotensin-converting enzyme inhibitors (ACE-inhibitors) and statins did not differ significantly between sexes. The use of diuretics was more frequent in females.

The probability of death of any cause was significantly higher in females during the five years of follow-up (17.6% vs. 11.8%; HR for female sex 1.54; CI 1.28–1.85; p<0.0001; Fig 1).

Matched cohort

The matched cohort included 1604 patients; 802 patients of either sex. Table 2 presents the clinical characteristics of the matched cohort. Clinical parameters regarding cardiovascular risk factors and revascularization therapy were equally distributed between the sexes with age nearly balanced (67.5 years in females versus 67.0 years in males, p = 0.153). Serum creatinine
was significantly higher in males than in females. No statistically significant differences were observed with respect of pharmaceutical therapy with the exception of ACE inhibitors which were less often administered in females (89.7% versus 92.8%, *p* = 0.034). Almost all patients underwent coronary angiography (99.5%) in both sexes. The prevalence of non-obstructive CAD was non-significantly more frequent in females (3.4% in females versus 2.0% in males, *p* = 0.122). Prevalence of one-vessel CAD was significantly more often in females, a three-vessel CAD predominated in males.

Over the entire follow-up period of five years, the mortality rates of female and male patients of the matched cohort did not differ significantly although a trend towards a poorer survival in females was observed (13.6% versus 11.7%; HR for female sex 1.14; CI 0.86–1.49; *p* = 0.359; Fig 2). However, when restricting the analysis to the first year of follow-up, female patients had a significantly worse outcome (mortality of 5.7% in females versus 3.6% in males; HR 1.61; CI 1.01–2.56; *p* = 0.045; Fig 3). The mortality between years 2 and 5 was practically

| Table 1. Patient characteristics in the complete cohort (n = 3,840) at baseline hospitalization. |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Clinical data | Females **n = 994** | Males **n = 2846** | **P** |
| Age (years), mean (SD) | 68.7 (11.9) | 61.0 (12.2) | `<0.001` |
| Hypertension, n (%) | 745 (74.9) | 1853 (65.1) | `<0.001` |
| Diabetes mellitus, n (%) | 255 (25.7) | 549 (19.3) | `<0.001` |
| Smokers, n (%) | 272 (27.4) | 1542 (54.2) | `<0.001` |
| Creatinine(mg/dl), mean (SD) | 1.2 (0.5) | 1.3 (0.2) | `<0.001` |
| Previous AMI, n (%) | 102 (10.3) | 386 (13.6) | 0.008 |
| Non-SR, n (%) | 79 (7.9) | 166 (5.8) | 0.023 |
| CK max (U/l), mean (SD) | 1526 (1583) | 2017 (2385) | `<0.001` |
| LVEF (%),mean (SD) | 52.6 (13.4) | 52.0 (13.0) | 0.177 |
| Coronary angiography, n (%) | 986 (99.2) | 2836 (99.6) | 0.125 |
| Non-obstructive CAD, n (%) | 52 (5.2) | 69 (2.4) | `<0.001` |
| One-vessel CAD, n (%) | 357 (35.9) | 924 (32.5) | 0.052 |
| Two-vessel CAD, n (%) | 258 (26.0) | 790 (27.8) | 0.291 |
| Three-vessel CAD, n (%) | 327 (32.9) | 1063 (37.4) | 0.013 |
| Therapy | | | |
| PCI, n (%) | 852 (85.7) | 2589 (91.0) | `<0.001` |
| CABG, n (%) | 28 (2.8) | 84 (3.0) | 0.914 |
| Thrombolysis n (%) | 24 (2.4) | 60 (2.1) | 0.658 |
| Conservative, n (%) | 90 (9.1) | 113 (4.0) | `<0.001` |
| ASS, n (%) | 964 (97.0) | 2759 (96.9) | 1.000 |
| Betablockers, n (%) | 921 (92.7) | 2609 (91.7) | 0.362 |
| ACE inhibitors, n (%) | 880 (88.5) | 2550 (89.6) | 0.379 |
| Statins, n (%) | 829 (83.4) | 2414 (81.0) | 0.311 |
| Diuretics, n (%) | 472 (47.5) | 1195 (42.0) | 0.003 |
| Mortality | | | |
| 5-year all-cause, n (%) | 175 (17.6) | 337 (11.8) | `<0.0001` |

ACE inhibitor: angiotensin-converting enzyme inhibitor, AMI: myocardial infarction, ASS: acetylsalicylic acid, CABG: coronary artery bypass grafting, CAD: coronary artery disease, CK max: maximal level of creatine kinase, LVEF: left ventricular ejection fraction, PCI: percutaneous coronary intervention, SD: standard deviation, SR: sinus rhythm

https://doi.org/10.1371/journal.pone.0186783.t001

No statistically significant differences were observed with respect of pharmaceutical therapy with the exception of ACE inhibitors which were less often administered in females (89.7% versus 92.8%, *p* = 0.034). Almost all patients underwent coronary angiography (≥99.5%) in both sexes. The prevalence of non-obstructive CAD was non-significantly more frequent in females (3.4% in females versus 2.0% in males, *p* = 0.122). Prevalence of one-vessel CAD was significantly more often in females, a three-vessel CAD predominated in males.

Over the entire follow-up period of five years, the mortality rates of female and male patients of the matched cohort did not differ significantly although a trend towards a poorer survival in females was observed (13.6% versus 11.7%; HR for female sex 1.14; CI 0.86–1.49; *p* = 0.359; Fig 2). However, when restricting the analysis to the first year of follow-up, female patients had a significantly worse outcome (mortality of 5.7% in females versus 3.6% in males; HR 1.61; CI 1.01–2.56; *p* = 0.045; Fig 3). The mortality between years 2 and 5 was practically

ACE inhibitor: angiotensin-converting enzyme inhibitor, AMI: myocardial infarction, ASS: acetylsalicylic acid, CABG: coronary artery bypass grafting, CAD: coronary artery disease, CK max: maximal level of creatine kinase, LVEF: left ventricular ejection fraction, PCI: percutaneous coronary intervention, SD: standard deviation, SR: sinus rhythm

https://doi.org/10.1371/journal.pone.0186783.t001

was significantly higher in males than in females. No statistically significant differences were observed with respect of pharmaceutical therapy with the exception of ACE inhibitors which were less often administered in females (89.7% versus 92.8%, *p* = 0.034). Almost all patients underwent coronary angiography (≥99.5%) in both sexes. The prevalence of non-obstructive CAD was non-significantly more frequent in females (3.4% in females versus 2.0% in males, *p* = 0.122). Prevalence of one-vessel CAD was significantly more often in females, a three-vessel CAD predominated in males.

Over the entire follow-up period of five years, the mortality rates of female and male patients of the matched cohort did not differ significantly although a trend towards a poorer survival in females was observed (13.6% versus 11.7%; HR for female sex 1.14; CI 0.86–1.49; *p* = 0.359; Fig 2). However, when restricting the analysis to the first year of follow-up, female patients had a significantly worse outcome (mortality of 5.7% in females versus 3.6% in males; HR 1.61; CI 1.01–2.56; *p* = 0.045; Fig 3). The mortality between years 2 and 5 was practically
identical between both sexes (8.1% in men versus 7.9% in women; HR 0.93; CI 0.66–1.32; p = 0.693; Fig 4).

Comparison between unmatched and matched females

No matching male counterpart was found for 192 females (19.3% of all female patients), because it was impossible to find absolute correspondence in all of the matching criteria. Table 3 shows the comparison between unmatched and matched females. There were substantial and statistically significant differences in many of the characteristics with the unmatched females being markedly older, suffering more frequently from diabetes mellitus and hypertension and showing a significantly higher rate of non-obstructive CAD (13.0% in unmatched females versus 3.4% in matched females, p<0.001). Rates of revascularization by PCI were strikingly less frequent in unmatched females compared to matched females (49.0% versus 94.5%, p<0.001) and unmatched females were more often treated conservatively (28.6% versus 4.4%, p<0.001).

Not surprisingly, the survival of the unmatched females was also substantially poorer compared to matched females (5-year mortality of 34.4% versus 13.6%; HR = 2.89; CI 2.13–3.93; p = <0.0001; Fig 5).

Comparison between unmatched and matched males

Contrary to females, comparison between unmatched and matched males reveals a significant younger age and a lower prevalence of hypertension and diabetes mellitus for the unmatched patients. There was no statistical significant difference regarding the non-obstructive or obstructive CAD between these groups. Table 4 shows the comparison between unmatched and matched males.

In contrast to females, survival rates between unmatched and matched males were similar (11.9% versus 11.7%; HR = 0.98; CI 0.77–1.24; p = 0.854; Fig 6). Note that also the survival
rates between matched and unmatched males were also similar during the first year after the index AMI (p = 0.172, detailed data not shown).

### Discussion

In agreement with previous studies [1,4,28–31], female post-infarction patients included in our prospective cohort study had a significantly higher mortality risk compared to males. Our data agree with previous explanations of this difference by female patients being older [4–7], having a higher prevalence of comorbidities such as hypertension and diabetes [4–6,8] and of non-obstructive CAD [12–16], being subject to a less invasive diagnostic [6,32] or therapeutic approach [6,33–36] as well as by the composite of different variables [37]. Indeed, comparison of Figs 5 and 6 shows that while the subgroup of sex-matched males was, in terms of post-AMI survival, representative of all the males, this was not the case for females. Not only the
previously reported risk factors but also their clinically more severe combinations are more frequent among females compare to males.

Aim of the matching analysis was to generate sets of females and males that were comparable regarding relevant risk factors in order to compare the sex-specific risk in a fair and systematic manner.

![Fig 2. Probabilities of death stratified by sex in the cohort of matched patients.](https://doi.org/10.1371/journal.pone.0186783.g002)

Previously reported risk factors but also their clinically more severe combinations are more frequent among females compared to males.

Aim of the matching analysis was to generate sets of females and males that were comparable regarding relevant risk factors in order to compare the sex-specific risk in a fair and systematic manner.

![Fig 3. Probabilities of death stratified by sex in the sex-matched cohort during the first year after the index infarction.](https://doi.org/10.1371/journal.pone.0186783.g003)
Importantly—as a result of the strict matching process—the oldest and sickest females were excluded from the matched cohort. Unmatched females had a higher risk factor burden, suffered more often from non-obstructive CAD, and had an almost 3-fold increase in 5-year mortality compared to those for whom a corresponding male patient was found.

In a matched cohort with the potentially influencing variables balanced, all-cause mortality during 5-year follow-up did not differ significantly between sexes over the whole 5-year follow-up period. However, we observed a significantly increased mortality risk in females during the first year of follow-up (HR 1.61; p = 0.045). Since the matched criteria can be excluded as reasons for the observed sex-specific mortality difference, other clinical and non-clinical aspects need to be considered as possible explanations for the observed mortality difference.

From the clinical point of view, factors such as time to PCI or thrombolysis as well as different pathologies leading to infarction such as dynamic obstruction, endothelial dysfunction or stress cardiomyopathy need to be taken into account. We could not evaluate all these possibilities in our matching analysis since the matching sub-groups would become too small and non-representative.

When recruitment for the ISAR-RISK [17] and ART [18] studies was initiated, distinctive knowledge about the mortality impact of the symptoms-to-balloon time [38–40] was only evolving. Consequently, these data were not routinely collected. We cannot exclude their influence on the observed mortality difference. However, we assume that treatment in females could not have been significantly delayed, as higher ischemic burden would have led to significantly increased CK-levels or impaired left ventricular function compared to males, which was not the case in the matched cohort.

Former studies reported higher renal dysfunction in female ST-elevation myocardial infarction (STEMI) patients and detected equal increment of mortality in both sexes in case of renal impairment [41,42]. In our cohort, males showed a decreased renal function compared to females in both the total and matched cohort. Still, female mortality exceeded that of males. This observation is even more surprising in this context.

Leaving the clinical aspects aside, a number of studies revealed non-clinical sex-specific factors such as socioeconomic status or depression contributing to worse outcome in female
compared to males, female AMI survivors present more often with psychological stress. They have lower scores on mental health status [46], show a greater functional decline and poorer health-related quality of life [47–53] and also suffer more frequently from depression [54]. At the same time, psychosocial factors are known to play an important role in post-AMI recovery and to predict 1-year cardiac mortality, independent of the severity of cardiac disease [45,46,51]. Correspondingly, family life status is known to influence post-AMI survival [45,55,56]. As we did not have the data to assess social status, marital status, quality of life or presence of depressive symptoms in this cohort, we cannot exclude these non-clinical factors from a partial influence on the detected mortality difference during the first year after AMI.

Equally importantly, autonomic function might play a role in respect of post-AMI mortality rates independently of clinical and social sex-specific differences. Measures of autonomic regulation processes have been proven as independent and useful risk stratification parameters.

Table 3. Patient characteristics of unmatched and matched females (n = 994).

|                           | Unmatched Females n = 192 | Matched Females n = 802 | P     |
|---------------------------|---------------------------|-------------------------|-------|
| **Clinical data**         |                           |                         |       |
| Age (years), mean (SD)    | 73.7 (13.9)               | 67.5 (11.1)             | <0.001|
| Hypertension, n (%)       | 132 (68.8)                | 613 (76.4)              | 0.034 |
| Diabetes mellitus, n (%)  | 63 (32.8)                 | 192 (23.9)              | 0.015 |
| Smokers, n (%)            | 46 (24.0)                 | 226 (28.2)              | 0.276 |
| Creatinine (mg/dl), mean (SD) | 1.21 (0.52)         | 1.10 (0.52)             | 0.005 |
| Previous AMI, n (%)       | 52 (27.1)                 | 50 (6.2)                | <0.001|
| Non-SR, n (%)             | 45 (23.4)                 | 34 (4.2)                | <0.001|
| CK max (UI/l), mean (SD)  | 1300 (1443)               | 1580 (1612)             | 0.011 |
| LVEF (%), mean (SD)       | 49.3 (18.8)               | 53.4 (11.7)             | <0.001|
| Coronary angiography, n (%) | 188 (97.9)               | 798 (99.5)              | 0.079 |
| Non-obstructive CAD, n (%) | 25 (13.0)                 | 27 (3.4)                | <0.001|
| One-vessel CAD, n (%)     | 47 (24.5)                 | 310 (38.7)              | <0.001|
| Two-vessel CAD, n (%)     | 36 (18.8)                 | 222 (27.7)              | 0.015 |
| Three-vessel CAD, n (%)   | 84 (43.8)                 | 243 (30.3)              | 0.001 |
| **Therapy**               |                           |                         |       |
| PCI, n (%)                | 94 (49.0)                 | 758 (94.5)              | <0.001|
| CABG, n (%)               | 22 (11.5)                 | 6 (0.7)                 | <0.001|
| Thrombolysis, n (%)       | 21 (10.9)                 | 3 (0.4)                 | <0.001|
| Conservative, n (%)       | 55 (28.6)                 | 35 (4.4)                | <0.001|
| ASS, n (%)                | 183 (95.3)                | 781 (97.4)              | 0.204 |
| Betablockers, n (%)       | 168 (87.5)                | 753 (93.9)              | 0.004 |
| ACE inhibitors, n (%)     | 161 (83.9)                | 719 (89.7)              | 0.033 |
| Statins, n (%)            | 152 (79.2)                | 677 (84.4)              | 0.099 |
| Diuretics, n (%)          | 111 (57.8)                | 361 (45.0)              | 0.002 |
| **Mortality**             |                           |                         |       |
| 5-year all-cause, n (%)   | 66 (34.4)                 | 109 (13.6)              | <0.001|

ACE inhibitor: angiotensin-converting enzyme inhibitor, AMI: myocardial infarction, ASS: acetylsalicylic acid, CABG: coronary artery bypass grafting, CAD: coronary artery disease, CK max: maximal level of creatine kinase, LVEF: left ventricular ejection fraction, PCI: percutaneous coronary intervention, SD: standard deviation, SR: sinus rhythm

https://doi.org/10.1371/journal.pone.0186783.t003
However, studies investigating the impact of sex-dependent differences in cardiac autonomic nervous system on the outcome after AMI are rare and have been so far inconclusive. Finally, the possibility that the early divergence in mortality risk in our matched cohort is due to a play of chance cannot be entirely excluded. Despite the number of the confounders that we could not have included in the matching process, our observations have important clinical implications. The excess mortality among females in the matched subgroups was observed during first year after the index AMI. Female AMI patients should therefore be followed more actively in the early post-AMI stages with more frequent follow-up clinical assessments at least in the first year after the event. Attention should be given to psychological and psycho-social factors in female patients with appropriate referrals to relevant specialists. Psychological support through specialists’ sessions and/or patient self-supporting groups for inter-patient communication and discussion should be considered.

Since the confounders that we have used for matching the sex groups are frequently used in guidelines and consensus proposals for post-AMI clinical care, our results also suggest that it is not fully appropriate to rely on evidence obtained in studies of predominantly male patients when treating female patients. Separate studies in female patients are needed to confirm whether the male-based evidence is appropriate or whether different guideline criteria are needed for both sexes.

Limitations
Several limitations of our study need to be considered. In the original ISAR-Risk and ART studies, no detailed information was collected about clinical data regarding symptoms-to-balloon-time or coronary pathology including endothelial dysfunction causing the myocardial
infarction. Apart from smoking, we are unable to include any data on pre-AMI lifestyles. Also, socioeconomic aspects, family support and the prevalence of depression were not assessed. We can only assume that these factors had substantial impact on mortality rates in the matched cohort, but cannot exclude other so far unknown factors.

Although the identification of the 1:1 matching groups was performed using previously proposed factors contributing to the survival differences, some differences between the matched groups could not have been eliminated. Not only were the women in the case-matched analysis less frequently treated with ACE inhibitors, they were also tiny bit older and suffered more frequently from a non-obstructive CAD. It was impossible to include pharmaceutical treatments (including that by ACE inhibitors) into the matching procedure, as the matched groups would have been too small and non-representative.

As risk profiles between sexes differed substantially—especially regarding age—it was impossible to find a female-male match in one fifth of female patients. More liberal matching criteria could have been considered but this would have led to groups differing relevantly in

Table 4. Patient characteristics of unmatched and matched males (n = 2846).

| Clinical data | Unmatched Males n = 2044 | Matched Males n = 802 | P |
|---------------|--------------------------|----------------------|---|
| Age (years), mean (SD) | 58.7 (11.9) | 67.0 (10.7) | <0.001 |
| Hypertension, n (%) | 1240 (60.6) | 613 (76.4) | <0.001 |
| Diabetes mellitus, n (%) | 357 (17.5) | 192 (23.9) | <0.001 |
| Smokers, n (%) | 1316 (64.4) | 226 (28.2) | <0.001 |
| Creatinine (mg/dl), mean (SD) | 1.22 (0.42) | 1.25 (0.41) | 0.008 |
| Previous AMI, n (%) | 336 (16.4) | 50 (6.2) | <0.001 |
| Non-SR, n (%) | 132 (6.5) | 34 (4.2) | 0.029 |
| CK max (U/l), mean (SD) | 2095 (2438) | 1819 (2232) | 0.016 |
| LVEF (%), mean (SD) | 51.5 (13.6) | 53.4 (11.3) | 0.008 |
| Coronary angiography, n (%) | 2037 (99.7) | 799 (99.6) | 1.0 |
| Non-obstructive CAD, n (%) | 53 (2.6) | 16 (2.0) | 0.425 |
| One-vessel CAD, n (%) | 685 (33.5) | 239 (29.8) | 0.063 |
| Two-vessel CAD, n (%) | 562 (27.5) | 228 (28.4) | 0.650 |
| Three-vessel CAD, n (%) | 744 (36.4) | 319 (39.8) | 0.103 |

| Therapy | | | |
| PCI, n (%) | 1828 (89.4) | 761 (94.9) | <0.001 |
| CABG, n (%) | 77 (3.8) | 7 (0.9) | <0.001 |
| Thrombolysis n (%) | 57 (2.8) | 3 (0.4) | <0.001 |
| Conservative, n (%) | 82 (4.0) | 31 (3.9) | 0.942 |
| ASS, n (%) | 1975 (96.6) | 784 (97.8) | 0.145 |
| Betablockers, n (%) | 1868 (91.4) | 741 (92.4) | 0.425 |
| ACE inhibitors, n (%) | 1806 (88.4) | 744 (92.8) | 0.001 |
| Statins, n (%) | 1717 (84.0) | 697 (86.9) | 0.059 |
| Diuretics, n (%) | 847 (41.4) | 348 (43.4) | 0.364 |

| Mortality | | |
| 5-year all-cause, n (%) | 243 (11.9) | 94 (11.7) | 0.952 |

ACE inhibitor: angiotensin-converting enzyme inhibitor, AMI: myocardial infarction, ASS: acetylsalicylic acid, CABG: coronary artery bypass grafting, CAD: coronary artery disease, CK max: maximal level of creatine kinase, LVEF: left ventricular ejection fraction, PCI: percutaneous coronary intervention, SD: standard deviation, SR: sinus rhythm

https://doi.org/10.1371/journal.pone.0186783.t004
important confounding factors. Since the number of females without an adequate match was already substantial when using 1:1 matching, we decided against a more flexible form of matching, e.g. 1:2 or 1:3, as the number of unmatched females would have been substantially increased.

Our data are based on patient recruitment between 1996 and 2005. Both medical therapy and revascularization techniques are improving over time. Particularly, the use of drug eluting stents and dual antiplatelet therapy evolved since the initial recruitment. However, as far as these clinical advances are concerned, we can safely assume that at each time point, they would have been applied to female and male patients similarly. It is therefore not likely that clinical advances over study duration impacted on the mortality differences. Finally, the retrospective nature of the analysis of prospectively-collected data needs to be acknowledged.

**Conclusion**

In this study, a typical cohort of AMI survivors was investigated with focus on sex-specific mortality. After matching females with 1:1 corresponding males of the same age, LVEF, cardiovascular risk factors and revascularization therapy, sex differences in post AMI survival could not be fully eliminated, particularly during the first year after the infarction. This finding is rather surprising and of clinical relevance.

Remaining excess female mortality might be, at least partly, explained by different pathophysiology of CAD in females and reduced applicability of invasive therapeutic approaches. Non-clinical variables including quality of life, family status and negative psychosocial responses triggered by AMI have to be considered. Nevertheless, we believe that our findings should encourage physicians to attend female AMI survivors with increased attention to prevent worse outcome in the future. In particular, our results appear to suggest that female post-AMI patients should be followed more actively with more frequent clinical and psychological assessments and support during at least the first year after AMI.

---

**Fig 6. Probabilities of death comparing males included and not included in the sex-matched cohort.**

Light blue and dark blue lines and bands correspond to males included (n = 802) and not included (n = 2044) in the sex-matched cohort, respectively. Further explanations correspond to Fig 5. HR–hazard ratio of men not included vs. included in the sex-matched cohort.

https://doi.org/10.1371/journal.pone.0186783.g006
Supporting information

S1 Table. Study raw data. PtNo: Patient Number, AMI: acute myocardial infarction, SR: sinus rhythm, CKmax: maximal level of creatine kinase, LVEF: left ventricular ejection fraction, CAD: coronary artery disease, ASS: acetylsalicylic acid, ACE_inhibitors: angiotensin-converting enzyme inhibitor, CSE_inhibitors: cholesterol synthesis enzyme inhibitor, fup_time: follow-up time.

(XLSX)

Acknowledgments

We would like to thank the authors and conductors of the ISAR-Risk and ART-study for kindly allowing us access to their data; namely Axel Bauer, Raphael Schneider, Kurt Ulm, Anke Joeinig, Raphael Stich, Antti Kviniemi, Heikki Huikuri, Albert Schöming, Jørgen K. Kanders, Vijayapraveena Paruchuri, Xiaoyun Yang. Also, we thank Anna Berkefeld, Daniel Sinnecker and Michael Dommasch for providing critical comments on the study.

Author Contributions

Conceptualization: Romy Ubrich, Bernhard Haller, Georg Schmidt.
Data curation: Petra Barthel, Alexander Müller.
Formal analysis: Petra Barthel, Bernhard Haller, Katerina Hnatkova.
Methodology: Romy Ubrich, Bernhard Haller, Georg Schmidt.
Software: Alexander Müller.
Validation: Petra Barthel.
Visualization: Petra Barthel, Katerina Hnatkova, Marek Malik.
Writing – original draft: Romy Ubrich, Bernhard Haller, Marek Malik, Georg Schmidt.
Writing – review & editing: Romy Ubrich, Bernhard Haller, Katharina Maria Huster, Alexander Steger, Marek Malik, Georg Schmidt.

References

1. Buchholz EM, Butala NM, Rathore SS, Dreyer RP, Lansky AJ, Krumholz HM. Sex differences in long-term mortality after myocardial infarction: a systematic review. Circulation. 2014; 130(9):757–67. https://doi.org/10.1161/CIRCULATIONAHA.114.009480 PMID: 25052403
2. Wijnbergen I, Tijsen J, van ’t Veer M, Michels R, Pijs NH. Gender differences in long-term outcome after primary percutaneous intervention for ST-segment elevation myocardial infarction. Catheter Cardiovasc Interv. 2013; 82(3):379–84. https://doi.org/10.1002/cud.24800 PMID: 23553888
3. Ciambrone G, Kaski JC. The importance of gender differences in the diagnosis and management of cardiovascular disease. Curr Pharm Des. 2011; 17(11):1079–81. PMID: 21449887
4. Otten AM, Maas AH, Ottervanger JP, Kloosterman A, van ’t Hof AW, Dambrink JH, et al. Is the difference in outcome between men and women treated by primary percutaneous coronary intervention age dependent? Gender difference in STEMI stratified on age. Eur Heart J Acute Cardiovasc Care. 2013; 2(4):334–41. https://doi.org/10.1177/2048872612475270 PMID: 24338292
5. Eitel I, Desch S, de Waha S, Fuernau G, Gutberlet M, Schuler G, et al. Sex differences in myocardial salvage and clinical outcome in patients with acute reperfused ST-elevation myocardial infarction: advances in cardiovascular imaging. Circ Cardiovasc Imaging. 2012; 5(1):119–26. https://doi.org/10.1161/CIRCIMAGING.111.965467 PMID: 22028459
6. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress
Sex differences in AMI outcomes

Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines National Quality Improvement Initiative. J Am Coll Cardiol. 2005; 45(6):832–37. https://doi.org/10.1016/j.jacc.2004.11.055 PMID: 15766815

7. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986; 111:383–90. PMID: 3946178

8. Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006; 47(3 Suppl):S4–S20. https://doi.org/10.1016/j.jacc.2005.01.072 PMID: 16458170

9. Leuzzi C, Sangiorgi GM, Modena MG. Gender-specific aspects in the clinical presentation of cardiovascular disease. Fundam Clin Pharmacol. 2010; 24(6):711–17. https://doi.org/10.1111/j.1472-8206.2010.00873.x PMID: 20840353

10. Shin JY, Martin R, Suls J. Meta-analytic evaluation of gender differences and symptom measurement strategies in acute coronary syndromes. J Pain Symptom Manage. 2005; 30(6):553–62. https://doi.org/10.1016/j.jpainsymman.2005.06.004 PMID: 16376742

11. Chen W, Woods SL, Wilkie DJ, Puntilllo KA. Gender differences in symptom experiences of patients with acute coronary syndromes. J Pain Symptom Manage. 2005; 30(6):553–62. https://doi.org/10.1016/j.jpainsymman.2005.06.004 PMID: 16376742

12. Cenko E, Bugiardi R. Vasotonic Angina as a Cause of Myocardial Ischemia in Women. Cardiovasc Drugs Ther. 2015; 29(4):339–45. https://doi.org/10.1007/s10557-015-6595-4 PMID: 26017335

13. Pepine CJ, Ferdinand KC, Shaw LJ, Light-McGroary KA, Shah RU, Gulati M, et al. Emergence of Non-obstructive Coronary Artery Disease: A Woman’s Problem and Need for Change in Definition on Angiography. J Am Coll Cardiol. 2015; 66(17):1918–33. https://doi.org/10.1016/j.jacc.2015.08.876 PMID: 26493665

14. Bugiardi R, Bairey Merz CN. Angina with “normal” coronary arteries: a changing philosophy. JAMA. 2005; 293(4):477–84. https://doi.org/10.1001/jama.293.4.477 PMID: 15761433

15. Shaw LJ, Bugiardi R, Merz CN. Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol. 2009; 54(17):1561–75. https://doi.org/10.1016/j.jacc.2009.04.098 PMID: 19833255

16. Bugiardi R, Manfrini O, Pizzi C, Fontana F, Morgagni G. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation. 2004; 109(21):2518–23. https://doi.org/10.1161/01.CIR.0000128208.22378.E3 PMID: 15136498

17. Bauer A, Barthel P, Schneider R, Ulm K, Müller A, Joening A, et al. Improved stratification of autonomic regulation for risk prediction in post-infarction patients with preserved left ventricular ejection fraction (ISAR-Risk). Eur Heart J 2009; 30:576–83. https://doi.org/10.1093/eurheartj/ehn540 PMID: 19109245

18. Barthel P, Bauer A, Müller A, Huster KM, Kanters JK, Paruchuri V, et al. Spontaneous baroreflex sensitivity: prospective validation trial of a novel technique in survivors of acute myocardial infarction. Heart Rhythm 2012; 8:1288–94.

19. Barthel P, Schneider R, Bauer A, Ulm K, Schmitt C, Schömig A, et al. Risk stratification after acute myocardial infarction by heart rate turbulence. Circulation. 2003; 108(10):1221–6. https://doi.org/10.1161/01.CIR.0000087833.34082.89 PMID: 12939209

20. Sinnecker D, Dommasch M, Steger A, Berkefeld A, Hoppmann P, Müller A, et al. Expiration-Triggered Sinus Arrhythmia Predicts Outcome in Survivors of Acute Myocardial Infarction. J Am Coll Cardiol. 2016 May 17; 67(19):2213–20. https://doi.org/10.1016/j.jacc.2016.03.484 PMID: 27173032

21. Sinnecker D, Dirschinger RJ, Barthel P, Müller A, Morley-Davies A, Hapfelmeyer A, et al. Postextracysmotic blood pressure potentiation predicts poor outcome of cardiac patients. J Am Heart Assoc. 2014; 3 (3):e000857. https://doi.org/10.1161/JAHA.114.000857 PMID: 24895163

22. Rizas KD, Nieminen T, Barthel P, Zürn CS, Kähönen M, Vik J, et al. Sympathetic activity-associated periodic repolarization dynamics predict mortality following myocardial infarction. J Clin Invest. 2014; 124(4):1770–80. https://doi.org/10.1172/JCI70085 PMID: 24642467

23. Barthel P, Wensel R, Bauer A, Müller A, Wolf P, Ulm K, Huster KM, Francis DP, Malik M, Schmidt G. Respiratory rate predicts outcome after acute myocardial infarction: a prospective cohort study. Eur Heart J. 2013 Jun; 34(22):1644–50. https://doi.org/10.1093/eurheartj/ehs420 PMID: 23242188

24. Barthel P, Bauer A, Müller A, Huster KM, Kanters JK, Paruchuri V, et al. Spontaneous baroreflex sensitivity: prospective validation trial of a novel technique in survivors of acute myocardial infarction. Heart Rhythm. 2012; 9(8):1288–94. https://doi.org/10.1016/j.hrthm.2012.04.017 PMID: 22516186

25. King G, Zeng L. The danger of extreme counterfactuals. Political Analysis 2006; 14(2):131–59.

26. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983; 70:41–55.
27. Ho DE, Imai K, King G, Stuart EA. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference. J Stat Softw. 2011; 42(8):1–28.

28. Yu J, Mehran R, Grinfeld L, Xu K, Nikolsky E, Brodie BR, et al. Sex-based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: three year results from the HORIZONS-AMI trial. Catheter Cardiovasc Interv. 2015; 85(3):359–68. https://doi.org/10.1002/ccd.2511596

29. Birkemeyer R, Schneider H, Rillig A, Ebeling J, Akin I, Kische S, et al. Do gender differences in primary PCI mortality represent a different adherence to guideline recommended therapy? A multicenter observation. BMC Cardiovasc Disord. 2014; 14:71. https://doi.org/10.1186/1471-2261-14-71 PMID: 24893930

30. Chaudhry SI, Khan RF, Chen J, Dharmarajan K, Dodson JA, Masoudi FA, et al. National trends in recurrent AMI hospitalizations 1 year after acute myocardial infarction in Medicare beneficiaries: 1999–2010. J Am Heart Assoc. 2014; 3(5):e001197. https://doi.org/10.1161/JAHA.114.001197 PMID: 25249298

31. Anderson ML, Peterson ED, Brennan JM, Rao SV, Dai D, Anstrom KJ, et al. Short- and long-term outcomes of coronary stenting in women versus men: results from the National Cardiovascular Data Registry Centers for Medicare & Medicaid services cohort. Circulation. 2012; 126(18):2190–9. https://doi.org/10.1161/CIRCULATIONAHA.111.11369 PMID: 22988009

32. Skelding KA, Boga G, Sartorius J, Wood GC, Berger PB, Mascarenhas VH, et al. Frequency of coronary angiography and revascularization among men and women with myocardial infarction and their relationship to mortality at one year: an analysis of the Geisinger myocardial infarction cohort. J Interv Cardiol. 2013; 26(1):14–21. https://doi.org/10.1111/joc.12009 PMID: 23278363

33. Sulzgruber P, Koller L, Pavo N, El-Hamid F, Rothgerber DJ, Forster S, et al. Gender-related differences in elderly patients with myocardial infarction in a European Centre. Eur J Clin Investig. 2016; 46(1):60–9. https://doi.org/10.1111/eci.12587 PMID: 26575703

34. D’Onofrio G, Safdar B, Lichtman JH, Strait KM, Dreyer RP, Geda M, et al. Sex differences in reperfusion in young patients with ST-segment-elevation myocardial infarction: results from the VIRGO study. Circulation. 2015; 131(15):1324–32. https://doi.org/10.1161/CIRCULATIONAHA.114.012293 PMID: 25792558

35. Hvelplund A, Galatius S, Madsen M, Sørensen R, Madsen JK, Iversen AZ, et al. Significance of the invasive strategy after acute myocardial infarction on prognosis and secondary preventive medication: a nationwide study of 6364 women and 11,915 men. J Invasive Cardiol. 2012; 24(1):19–24. PMID: 22210585

36. Poon S, Goodman SG, Yan RT, Bugiardini R, Bierman AS, Eagle KA, et al. Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes. Am Heart J. 2012; 163(1):66–73. https://doi.org/10.1016/j.ahj.2011.09.025 PMID: 22172438

37. Lam CS, McEntegart M, Claggett B, Liu J, Skali H, Lewis E, et al. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2015; 17(3):301–12. https://doi.org/10.1002/ejhf.238 PMID: 25655011

38. Dreyer RP, Beltrame JF, Tavella R, Air T, Hoffmann B, Pati PK, et al. Evaluation of gender differences in Door-to-Ballooon time in ST-elevation myocardial infarction. Heart Lung Circ. 2013; 22(10):861–9. https://doi.org/10.1016/j.hlc.2013.03.078 PMID: 23628331

39. Hudson MP, Armstrong PW, O’Neil WW, Stebbins AL, Weaver WD, Widimsky P, et al. Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. Circ Cardiovasc Qual Outcomes. 2011; 4(2):183–92. https://doi.org/10.1161/CIRCOUTCOMES.110.945311 PMID: 21304097

40. Rathore SS, Curtis JP, Nallamothu BK, Wang Y, Foody JM, Kosiborod M, et al. Association of door-to-ballooon time and mortality in patients > or = 65 years with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2009; 104(9):1198–203. https://doi.org/10.1016/j.amjcard.2009.06.034 PMID: 19840562

41. Choi JS, Kim MJ, Kang YU, Kim CS, Bae EH, Ma SK, et al. Does gender influence the impact of impaired renal function on prognosis after ST-segment-elevated myocardial infarction? Cardiol J. 2013; 20(5):526–32. https://doi.org/10.5603/CJ.2013.0138 PMID: 24469877

42. Gevaert SA, De Bacquer D, Evrard P, Renard M, Beauloye C, Coussement P, et al. Renal dysfunction in STEMI-patients undergoing primary angioplasty: higher prevalence but equal prognostic impact in female patients; an observational cohort study from the Belgian STEMI registry. BMC Nephrol. 2013; 14:62. https://doi.org/10.1186/1471-2369-14-62 PMID: 23506004
43. Alter DA, Franklin B, Ko DT, Austin PC, Lee DS, Oh PI, et al. Socioeconomic status, functional recovery, and long-term mortality among patients surviving acute myocardial infarction. PLoS One. 2013; 8(6):e65130. https://doi.org/10.1371/journal.pone.0065130 PMID: 23755180

44. Wheeler A, Beltramé J, Tucker G, Air T, Ling LH, Schrader G. Depression and 5-year mortality in patients with acute myocardial infarction: analysis of the IDACC database. Aust NZ J Psychiatry. 2012; 46(7):669–75. https://doi.org/10.1177/0004867412449875 PMID: 22645397

45. Grunau GL, Ratner PA, Goldner EM, Sheps S. Is early- and late-onset depression after acute myocardial infarction associated with long-term survival in older adults? A population-based study. Can J Cardiol. 2006; 22(6):473–8. PMID: 16685310

46. Dreyer RP, Wang Y, Strait KM, Lorenze NP, D’Onofrio G, Bueno H, et al. Gender differences in the trajectory of recovery in health status among young patients with acute myocardial infarction: results from the variation in recovery: role of gender on outcomes of young AMI patients (VIRGO) study. Circulation. 2015; 131(22):1971–80. https://doi.org/10.1161/CIRCULATIONAHA.114.014503 PMID: 25862743

47. Dodson JA, Arnold SV, Reid KJ, Gill TM, Rich MW, Masoudi FA, et al. Physical function and independence 1 year after myocardial infarction: observations from the Translational Research Investigating Underlying Disparities in Recovery From Acute Myocardial Infarction: Patients’ Health Status Registry. Am Heart J. 2012; 163:790–96. https://doi.org/10.1016/j.ahj.2012.02.024 PMID: 22607856

48. Leung Yinko SS, Pelletier R, Behlouli H, Norris CM, Humphries KH, Pilote L, et al. Health-related quality of life in premature acute coronary syndrome: does patient sex or gender really matter? J Am Heart Assoc. 2014; 3(4). pii:e000901. https://doi.org/10.1161/JAHA.114.000901 PMID: 25074696

49. Brink E, Granqvist G, Karlsson BW, Hallberg LR. Health-related quality of life in women and men one year after acute myocardial infarction. Qual Life Res. 2005; 14:749–57. PMID: 16022067

50. Emery CF, Frid DJ, Engebretson TO, Alonzo AA, Fish A, Ferketich AK, et al. Gender differences in quality of life among cardiac patients. Psychosom Med. 2004; 66:190–7. PMID: 15039503

51. Beck CA, Joseph L, Bélish P, Pilote L; QOLAMI Investigators (Quality of life in acute myocardial infarction), et al. Predictors of quality of life 6 months and 1 year after acute myocardial infarction. Am Heart J. 2001; 142:271–9. https://doi.org/10.1067/mhj.2001.116758 PMID: 11479466

52. Cossette S, Frasure-Smith N, Lespérance F. Clinical implications of a reduction in psychological distress on cardiac prognosis in patients participating in a psychosocial intervention program. Psychosom Med. 2001; 63(2):257–66. PMID: 11292273

53. Norris CM, Hegadoren K, Pilote L. Depression symptoms have a greater impact on the 1-year health-related quality of life outcomes of women post-myocardial infarction compared to men. Eur J Cardiovasc Nurs. 2007; 6(2):92–8. https://doi.org/10.1016/j.ejcnurse.2006.05.003 PMID: 16843729

54. Frasure-Smith N, Lespérance F, Juneau M, Talajic M, Bourassa MG. Gender, depression, and one-year prognosis after myocardial infarction. Psychosom Med. 1999; 61(1):26–37. PMID: 10024065

55. Chandra V, Szklw M, Goldberg R, Tonascia J. The impact of marital status on survival after an acute myocardial infarction: a population-based study. Am J Epidemiol. 1983; 117:320–5. PMID: 6829559

56. Kilpi F, Kontinnen H, Silventoinen K, Martikainen P. Living arrangements as determinants of myocardial infarction incidence and survival: A prospective register study of over 300,000 Finnish men and women. Soc Sci Med. 2015; 133:93–100. https://doi.org/10.1016/j.soscimed.2015.03.054 PMID: 25863724

57. Ulbrich R, Barthel P, Berkefeld A, Hnatkova K, Huster KM, Dommasch M, et al. Electrocardiographic and cardiac autonomic indices—implications of sex-specific risk stratification in women after acute myocardial infarction. Curr Pharm Des. 2016; 22(25):3817–28. PMID: 26965489